Publications
5891 Results
- Journal / Conference
- J Amer Stat Assoc. 2025 Jul 15:1-10; publ online: 27 Aug 2025; doi: 10.1080/01621459.2025.2526703
- Year
- 2025
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217
Long-term effect estimation when combining clinical trial and observational follow-up datasets
- Journal / Conference
- ASH Annual Meeting (December 6-9, 2025, Orlando, FL). #3501 poster. Blood (2025) 146 (Supplement 1): 3501
- Year
- 2025
- Research Committee(s)
- Leukemia
- Study Number(s)
- MYELOMATCH
Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratification – an NCI myeloMATCH and SWOG report
- Journal / Conference
- ASH Annual Meeting (December 6-9, 2025, Orlando, FL). #1840 TIPs poster. Blood (2025) 146 (Supplement 1): 1840
- Year
- 2025
- Research Committee(s)
- Myeloma
- Study Number(s)
- S2005
S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) vs. venetoclax and rituximab (VR) in previously untreated Waldenstro¨m’s macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL)
- Journal / Conference
- ASH Annual Meeting (December 6-9, 2025, Orlando, FL). 3466 poster TIPs. Blood (2025) 146 (Supplement 1): 3466
- Year
- 2025
- Research Committee(s)
- Leukemia
- Study Number(s)
- MM1OA-S03
A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myeloMATCH substudy (MM1OA-S03)
- Journal / Conference
- ASH Annual Meeting (December 6-9, 2025, Orlando, FL), 2025. Abstract 1851 poster. Blood (2025) 146 (Supplement 1): 1851
- Year
- 2025
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study
- Journal / Conference
- San Antonio Breast Cancer Symposium (December 9-12, 2025, San Antonio, TX). Clin Cancer Res (2026) 32 (4_Supplement): PS3-01-15.
- Year
- 2025
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- Study Number(s)
- S1904
Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE): Cluster Randomized Controlled Trial of Decision Support for Breast Cancer Chemoprevention, SWOG 1904
- Journal / Conference
- San Antonio Breast Cancer Symposium (December 9-12, 2025, San Antonio, TX)
- Year
- 2025
- Research Committee(s)
- Breast
- Study Number(s)
- S1007
Sentinel Lymph Node Biopsy and Clinical Outcome of Patients with Node-Positive Breast Cancer in the RxPONDER Trial (S1007)
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #3624 poster
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80702
Sex differences in chemotherapy completion and adverse events among patients with colon cancer (CALGB/SWOG 80702) (Alliance)
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #LBA3509
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80702
Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance)
- Journal / Conference
- ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #LBA8671
- Year
- 2025
- Research Committee(s)
- Lung
- Study Number(s)
- S2302